• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nautilus Biotechnolgy Inc.

    2/13/23 4:15:52 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $NAUT alert in real time by email
    SC 13G 1 tm236459d4_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. ___)*

     

    Nautilus Biotechnology, Inc.

     

    (Name of Issuer)

     

    Common Stock, par value $0.0001

     

    (Title of Class of Securities)

     

    63909J108

     

    (CUSIP Number)

     

    December 31, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 63909J108  Page 2 of 7

     

    1.

    Name of Reporting Person

     

    Cercano Management LLC

     

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a)   ¨

    (b)   ¨

     

    3.

    SEC USE ONLY

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:

    5.

    Sole Voting Power

     

    0

     

    6.

    Shared Voting Power

     

    7,172,985

     

    7.

    Sole Dispositive Power

     

    0

     

    8.

    Shared Dispositive Power

     

    7,172,985

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,172,985

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) ¨

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    5.8% (1)

     

    12.

    Type of Reporting Person (see instructions)

     

    IA

     

           
    (1)Calculated in accordance with Rule 13(d)-3(d)(1)(i), promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and based on an aggregate total of 124,723,525 shares of the Issuer’s Common Stock outstanding as of October 28, 2022, as reported by the Issuer in its Quarterly Report for the period ended September 30, 2022, filed on Form 10-Q with the Securities and Exchange Commission (the “SEC”) on November 1, 2022.

     

     

     

     

    CUSIP No. 63909J108  Page 3 of 7

      

    1.

    Name of Reporting Person

     

    Christopher N. Orndorff

     

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a)   ¨

    (b)   ¨

     

    3.

    SEC USE ONLY

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:

    5.

    Sole Voting Power

     

    0

     

    6.

    Shared Voting Power

     

    7,172,985

     

    7.

    Sole Dispositive Power

     

    0

     

    8.

    Shared Dispositive Power

     

    7,172,985

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,172,985

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)  ¨

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    5.8% (1)

     

    12.

    Type of Reporting Person (see instructions)

     

    IN

           
    (1)Calculated in accordance with Rule 13(d)-3(d)(1)(i), promulgated under the Exchange Act, and based on an aggregate total of 124,723,525 shares of the Issuer’s Common Stock outstanding as of October 28, 2022, as reported by the Issuer in its Quarterly Report for the period ended September 30, 2022, filed on Form 10-Q with the SEC on November 1, 2022.

     

     

     

     

    CUSIP No. 63909J108  Page 4 of 7

     

    Item 1(a)

    Name of Issuer.

     

    Nautilus Biotechnology, Inc. (the “Issuer”)

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices.

     

    2701 Eastlake Avenue East

    Seattle, WA 98102

     

    Item 2(a) Name of Person Filing.
     

     

    Cercano Management LLC (the “Manager”)

    Christopher N. Orndorff (“Mr. Orndorff” and, together with the Manager, the “Reporting Persons”)

     

    Item 2(b)

    Address of Principal Business Office or, if none, Residence.

     

    The address of the principal business office of each of the Reporting Persons is:

     

     

    1110 112th Avenue NE

    Suite 202

    Bellevue, WA 98004

     

    Item 2(c) Citizenship.
     

     

    Manager:            Delaware

    Mr. Orndorff:    United States of America

     

    Item 2(d)

    Title of Class of Securities.

     

    Common Stock, $0.0001 par value

     

    Item 2(e)

     

    CUSIP Number.

     

    63909J108

     

    Item 3   If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
         
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ¨ Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
           
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

     

     

     

    CUSIP No. 63909J108  Page 5 of 7

     

      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with §240.13d–1(b)(1)(ii)(K).
           
        If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: _________________.

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

    a.Amount Beneficially Owned:

     

    Manager:7,172,985
    Mr. Orndorff:7,172,985

     

    b.Percent of Class:

     

    Manager:5.8%
    Mr. Orndorff:5.8%

     

    The aforementioned percentages were calculated in accordance with Rule 13(d)-3(d)(1)(i), promulgated under the Securities Exchange Act of 1934, as amended, and based on an aggregate total of 124,723,525 shares of the Issuer’s Common Stock outstanding as of October 28, 2022, as reported by the Issuer in its Quarterly Report for the period ended September 30, 2022, filed on Form 10-Q with the Securities and Exchange Commission on November 1, 2022.

     

    c.Number of shares as to which the person has:

     

    i.Sole power to vote or to direct the vote:

     

    Manager   0 
    Mr. Orndorff   0 

     

    ii.Shared power to vote or to direct the vote:

     

    Manager   7,172,985 
    Mr. Orndorff   7,172,985 

     

    iii.Sole power to dispose or to direct the disposition of:

     

    Manager   0 
    Mr. Orndorff   0 

     

     

     

     

    CUSIP No. 63909J108  Page 6 of 7

     

    iv.Shared power to dispose or to direct the disposition of:

      

    Manager   7,172,985 
    Mr. Orndorff   7,172,985 

     

    The Manager may be deemed to be the beneficial owner of the Issuer’s shares of Common Stock (the “Securities”) reported herein. The Manager acts as an investment adviser to certain clients holding managed accounts with the Manager pursuant to investment management agreements whereby all voting and investment discretion has been contractually allocated to the Manager, and such discretion may not be revoked with less than 61 days’ notice.

     

    Mr. Orndorff may also be deemed to be the beneficial owner of the Securities because he controls the Manager in his position as managing member of the Manager.

     

    The filing of this Statement shall not be construed as an admission that the Reporting Persons or any of their affiliates are the beneficial owner of any Securities reported herein for any purposes other than Section 13(d) of the Exchange Act.

     

    Item 5.Ownership of 5 Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following          ¨.

     

    Item 6.Ownership of More than 5 Percent on Behalf of Another Person.

     

    All of the Securities reported in this Statement are beneficially owned on behalf of investment advisory clients of the Reporting Persons, which have the right to receive or the power to direct the receipt of dividends from, or the proceeds from a sale of, such Securities. None of such clients individually owns more than five percent.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Item 7 is not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Item 8 is not applicable.

     

    Item 9.Notice of Dissolution of a Group.

     

    Item 9 is not applicable.

     

    Item 10.Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.141-11.

     

     

     

     

    CUSIP No. 63909J108  Page 7 of 7

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2023

    CERCANO MANAGEMENT LLC

       
      By: /s/ Christopher N. Orndorff
        Christopher N. Orndorff, President
       

    Date: February 13, 2023

     

       
      By: /s/ Christopher N. Orndorff
        Christopher N. Orndorff

     

     

     

    Get the next $NAUT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAUT

    DatePrice TargetRatingAnalyst
    12/5/2024$1.75Neutral → Sell
    Goldman
    6/27/2024$6.00Buy
    Guggenheim
    6/3/2024$3.00Hold
    Jefferies
    1/6/2022$8.00Equal-Weight
    Morgan Stanley
    11/2/2021Outperform
    Cowen & Co.
    8/4/2021$10.00Neutral
    Goldman Sachs
    7/13/2021$13.00Buy
    Jefferies
    More analyst ratings

    $NAUT
    SEC Filings

    View All

    SEC Form 10-Q filed by Nautilus Biotechnolgy Inc.

    10-Q - Nautilus Biotechnology, Inc. (0001808805) (Filer)

    7/31/25 4:35:28 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnolgy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)

    7/30/25 7:45:56 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnolgy Inc.

    SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

    6/24/25 4:42:31 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Treasurer Mowry Anna bought $11,488 worth of shares (15,000 units at $0.77), increasing direct ownership by 22% to 83,000 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    6/2/25 5:12:33 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Scientist Mallick Parag bought $9,885 worth of shares (13,500 units at $0.73), increasing direct ownership by 0.07% to 20,493,392 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    5/12/25 7:19:33 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CEO, President, and Secretary Patel Sujal M bought $76,918 worth of shares (77,233 units at $1.00), increasing direct ownership by 0.77% to 10,141,721 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/21/25 4:44:37 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nautilus Biotechnology downgraded by Goldman with a new price target

    Goldman downgraded Nautilus Biotechnology from Neutral to Sell and set a new price target of $1.75

    12/5/24 7:46:35 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Guggenheim initiated coverage on Nautilus Biotechnology with a new price target

    Guggenheim initiated coverage of Nautilus Biotechnology with a rating of Buy and set a new price target of $6.00

    6/27/24 7:49:37 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jefferies resumed coverage on Nautilus Biotechnology with a new price target

    Jefferies resumed coverage of Nautilus Biotechnology with a rating of Hold and set a new price target of $3.00

    6/3/24 8:53:10 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Epperly Melissa B,

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    6/25/25 4:37:40 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Posard Matthew L.

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    6/25/25 4:37:28 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Mcilwain Matthew S

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    6/25/25 4:37:16 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nautilus Biotechnology Reports Second Quarter 2025 Financial Results

    SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025. "In Q2, we achieved major milestones that underscore the continued advancement of our platform," said Sujal Patel, CEO of Nautilus Biotechnology. "Not only did we continue our momentum across both targeted and broadscale proteomic development efforts, but we also publicly shared the first scientific manuscript to feature novel data generated using the Nautilus Platform. The manuscript represents nearly a decade of pioneering work by our team and

    7/31/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics

    • Allen Institute to employ Iterative Mapping, Nautilus' single-molecule proteomics method, to investigate connection between tau protein and Alzheimer's disease • Agreement links the organizations' next-generation proteomics technology and neuroscience leadership to potentially unlock breakthrough therapeutics and biomarkers for neurodegenerative disease SEATTLE, July 30, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering single-molecule proteome analysis, today announced they have entered into an agreement with the Allen Institute focused on investigating the connection between the tau protein and neurodegenerative conditions such

    7/30/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025

    SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2025 before market open on Thursday, July 31, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters i

    7/15/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Leadership Updates

    Live Leadership Updates

    View All

    Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

    SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Nautilus after 25 years in product and marketing leadership roles at Agilent Technologies, most recently serving as Vice President and General Manager of Agilent's Mass Spectrometry division. He has held numerous leadership positions at Agilent, including in the Strategic Program Office and Certified Pre-Owned Instruments, CrossLab Services and Support, and Spectroscopy. "Ke

    9/17/24 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development

    SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development. Dr. Huber brings to Nautilus over 20 years of experience in biotechnology start-ups both in Europe and the US, most recently as founder, CTO and, ultimately, CEO of Quantapore, a company devoted to pioneering massively parallel, direct, single-molecule DNA and protein analytical tools. Prior to that, he he

    11/1/23 8:05:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology Appoints Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development

    SEATTLE, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced further expansion of its management team with the appointments of Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development. Both executives join the company's product development team. Eric Spence, Vice President of Instrument Engineering: Instrument engineering veteran Eric Spence comes to Nautilus from Genapsys, where he advanced through several positions of increasing responsibility leading the instrum

    8/1/22 4:05:00 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Financials

    Live finance-specific insights

    View All

    Nautilus Biotechnology Reports Second Quarter 2025 Financial Results

    SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025. "In Q2, we achieved major milestones that underscore the continued advancement of our platform," said Sujal Patel, CEO of Nautilus Biotechnology. "Not only did we continue our momentum across both targeted and broadscale proteomic development efforts, but we also publicly shared the first scientific manuscript to feature novel data generated using the Nautilus Platform. The manuscript represents nearly a decade of pioneering work by our team and

    7/31/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025

    SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2025 before market open on Thursday, July 31, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters i

    7/15/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology Reports First Quarter 2025 Financial Results

    SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. "In Q1, we saw continued development progress based on the results of internal verification and validation work we've done on our Tau proteoform assay," said Sujal Patel, CEO of Nautilus Biotechnology. "The assay's reproducibility, accuracy, dynamic range, and sample compatibility align closely with our anticipated launch specifications and with the requirements we continue to hear from potential customers and partners. We are confident that 202

    4/29/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc.

    SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

    11/14/24 4:31:50 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc. (Amendment)

    SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

    11/16/23 9:18:26 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc. (Amendment)

    SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

    3/1/23 3:30:45 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials